Nasdaq Dyn News Today

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) and Leap Therapeutics (NASDAQ:LPTX – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability. Institutional & Insider Ownership 96.7% of Dyne Therapeutics […]

Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $36.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 38.04% from the company’s […]

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been given an average rating of “Buy” by the eight analysts that are covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price […]

Morgan Stanley started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a report released on Tuesday, Briefing.com reports. The firm set an “overweight” rating and a $40.00 price target on the stock. Morgan Stanley’s price target indicates a potential upside of 57.11% from the company’s previous close. A number of other […]

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) have earned an average rating of “Buy” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price […]

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) traded down 3% on Thursday . The stock traded as low as $27.57 and last traded at $27.89. 552,733 shares were traded during mid-day trading, a decline of 75% from the average session volume of 2,206,098 shares. The stock had previously closed at $28.76. Wall Street Analysts […]

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been given an average rating of “Buy” by the seven research firms that are covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […]

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target hoisted by Chardan Capital from $20.00 to $31.00 in a research note issued to investors on Friday, Stock Target Advisor reports. The brokerage currently has a buy rating on the stock. Several other research firms have also weighed in on DYN. StockNews.com upgraded shares of […]

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price objective increased by Chardan Capital from $20.00 to $31.00 in a research report sent to investors on Friday morning, Stock Target Advisor reports. Chardan Capital currently has a buy rating on the stock. Several other equities research analysts have also recently issued reports on the stock. […]

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $22.57, for a total value of $4,164,187.57. Following the transaction, the insider now directly owns […]